| 产品描述: | Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity. Quisinostat can induce autophagy in neuroblastoma cells |
| 靶点: |
HDAC1:0.11 nM (IC50);HDAC2:0.33 nM (IC50);HDAC4:0.64 nM (IC50);HDAC10:0.46 nM (IC50);HDAC11:0.37 nM (IC50);HDAC3:4.86 nM (IC50);HDAC5:3.69 nM (IC50);HDAC8:4.26 nM (IC50);HDAC9:32.1 nM (IC50);HDAC6:76.8 nM (IC50);HDAC7:119 nM (IC50);Apoptosis; HDAC; Autophagy |
| 体内研究: |
Quisinostat (40 mg/kg; p.o.; once daily; for 3 days) acts as a potent HDAC1 inhibitor p21waf1,cip1 ZsGreen tumors in vivo. Quisinostat induces continuous H3 acetylation in tumor tissue in vivo. Quisinostat (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts |
| 参考文献: |
1. Arts J, et al. JNJ-26481585, a novel second-generation oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. 2. Vamsi Krishna Kommalapati, et al. Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells. Mol Cell Biochem. 2020 May;468(1-2):21-34. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.535 ml |
12.675 ml |
25.35 ml |
| 5 mM |
0.507 ml |
2.535 ml |
5.07 ml |
| 10 mM |
0.254 ml |
1.268 ml |
2.535 ml |
| 50 mM |
0.051 ml |
0.254 ml |
0.507 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |